Erlotinib Hydrochloride With or Without Bevacizumab in Treating Patients With Stage IV Non-small Cell Lung Cancer With Epidermal Growth Factor Receptor Mutations



Status:Active, not recruiting
Conditions:Lung Cancer, Cancer
Therapuetic Areas:Oncology
Healthy:No
Age Range:18 - Any
Updated:2/23/2019
Start Date:March 16, 2012
End Date:July 1, 2020

Use our guide to learn which trials are right for you!

A Randomized Phase II Trial of Erlotinib Alone or in Combination With Bevacizumab in Patients With Non-Small Cell Lung Cancer and Activating Epidermal Growth Factor Receptor Mutations

This randomized phase II trial studies how well erlotinib hydrochloride (Tarceva) with or
without bevacizumab (Avastin) works in treating patients with stage IV non-small cell lung
cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutations. Erlotinib
hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for
cell growth. Monoclonal antibodies, such as bevacizumab, may block tumor growth in different
ways by targeting certain cells. Bevacizumab may also stop the growth of NSCLC by blocking
the growth of new blood vessels necessary for tumor growth. It is not yet known whether
erlotinib hydrochloride is more effective when given alone or with bevacizumab in treating
patients with NSCLC.

PRIMARY OBJECTIVES:

I. To determine the progression-free survival of erlotinib (erlotinib hydrochloride) and
bevacizumab versus that of erlotinib alone for the purpose of deciding if the combination arm
is worth pursuing in a phase III trial.

SECONDARY OBJECTIVES:

I. To investigate the overall survival of erlotinib and bevacizumab versus erlotinib alone.

II. To investigate the response rate of erlotinib and bevacizumab versus erlotinib alone.

III. To investigate the progression-free survival in patients with exon deletion 19 or exon
21 L858R point mutations.

IV. To investigate the toxicity of erlotinib and bevacizumab versus erlotinib alone using
Common Terminology Criteria for Adverse Events (CTCAE) version 4.0.

TERTIARY OBJECTIVES:

I. To correlate EGFR mutations detected in plasma deoxyribonucleic acid (DNA) with those
detected in tumor DNA.

II. To estimate the prevalence of EGFR T790M resistance mutations from pretreatment tumor
biopsies using more sensitive mutation detection methods.

III. To investigate progression free survival of EGFR mutant NSCLC patients with and without
concurrent EGFR T790M detected from pre-treatment tumor specimen using allele specific
quantitative polymerase chain reaction (PCR).

IV. To prospectively evaluate the predictive value of plasma VEGF-A levels on progression
free survival in patients treated with erlotinib alone or in combination with bevacizumab.

OUTLINE: Patients are randomized to 1 of 2 treatment arms.

ARM A: Patients receive erlotinib hydrochloride orally (PO) once daily (QD) on days 1-21.

ARM B: Patients receive erlotinib hydrochloride as in Arm A and bevacizumab intravenously
(IV) over 30-90 minutes on day 1.

In both arms, courses repeat every 21 days in the absence of disease progression or
unacceptable toxicity.

After completion of study treatment, patients are followed up every 3-6 months for 6 years.

Inclusion Criteria:

- Histologic documentation of primary lung carcinoma, non-squamous histology with
activating epidermal growth factor receptor (defined as deletion 19 or exon 21 L858R
mutation); Note: EGFR mutation testing must be performed at a Clinical Laboratory
Improvement Amendments (CLIA) certified lab; either institutional or through a
commercial laboratory (e.g. Genzyme, Response Genetics, etc); the laboratory report
from the commercial laboratories report the specific mutations detected, and the
method of detecting the exon 19 and exon 21 L858R point mutations must be available

- Stage IV disease according to the 7th Edition of the American Joint Committee on
Cancer staging system

- Measurable disease

- Life expectancy of >= 12 months

- Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0 or 1

- Absolute neutrophil count (ANC) >= 1,500/mm^3 obtained =< 14 days prior to
randomization

- Platelet count >= 100,000/mm^3 obtained =< 14 days prior to randomization

- Hemoglobin >= 9.0 g/dL obtained =< 14 days prior to randomization

- Total bilirubin =< 1.5 x upper limit of normal (ULN) obtained =< 14 days prior to
randomization

- Serum glutamic oxaloacetic transaminase (SGOT) (aspartate aminotransferase [AST]) and
serum glutamate pyruvate transaminase (SGPT) (alanine aminotransferase [ALT]) =< 2.5 x
ULN in patients without liver or bone metastases; < 5 x ULN in patients with liver or
bone metastases obtained =< 14 days prior to randomization

- Cockcroft-Gault calculated creatinine clearance of >= 45 ml/min or creatinine =< 1.5 x
ULN obtained =< 14 days prior to randomization

- Urine dipstick proteinuria < 2+ or urine protein/creatinine (UPC) ratio =< 1.0
obtained =< 14 days prior to randomization

- Note: patients discovered to have >= 2 + proteinuria on dipstick urinalysis at
baseline should undergo a 24-hour urine collection and must demonstrate =< 1 g of
protein in 24 hours

- Negative pregnancy test done =< 7 days prior to randomization, for women of
childbearing potential only

- Provide informed written consent

- Willing to return to Academic and Community Cancer Research United (ACCRU) enrolling
institution for follow-up

- Willing to provide tissue and blood samples for correlative research purposes

Exclusion Criteria:

- Mixed, non-small cell and small cell tumors or mixed adenosquamous carcinomas with a
predominant squamous component

- Prior chemotherapy or treatment for metastatic non-small cell lung cancer

- Any of the following:

- Pregnant women

- Nursing women

- Men or women of childbearing potential who are unwilling to employ adequate
contraception

- Co-morbid systemic illnesses or other severe concurrent disease which, in the judgment
of the investigator, would make the patient inappropriate for entry into this study or
interfere significantly with the proper assessment of safety and toxicity of the
prescribed regimens

- Immunocompromised patients (other than that related to the use of corticosteroids)
including patients known to be human immunodeficiency virus (HIV) positive, per
medical doctor (MD) discretion

- Uncontrolled intercurrent illness including, but not limited to, ongoing or active
infection, or psychiatric illness/social situations, or any other medical condition
that would limit compliance with study requirements

- Receiving any other investigational agent which would be considered as a treatment for
the primary neoplasm

- Other active malignancy =< 3 years prior to randomization; EXCEPTIONS: non melanotic
skin cancer or carcinoma-in-situ of the cervix; Note: if there is a history of prior
malignancy, they must not be receiving other specific treatment (i.e. hormonal
therapy) for their cancer

- History of myocardial infarction or other evidence of arterial thrombotic disease
(angina), symptomatic congestive heart failure (New York Heart Association >= grade
2), unstable angina pectoris, or cardiac arrhythmia; Note: allowed only if patient has
no evidence of active disease for at least 6 months prior to randomization

- History of cerebral vascular accident (CVA) or transient ischemic attack (TIA) =< 6
months prior to randomization

- History of bleeding diathesis or coagulopathy

- Inadequately controlled hypertension (systolic blood pressure of > 150 mmHg or
diastolic pressure > 100 mmHg on anti-hypertensive medications); Note: history of
hypertensive crisis or hypertensive encephalopathy not allowed

- Current or recent (=< 10 days prior to randomization) use of aspirin (> 325 mg/day),
clopidogrel (> 75 mg/day), or prasugrel (> 10 mg/day)

- Serious non-healing wound, ulcer, bone fracture, or have undergone a major surgical
procedure, open biopsy, or significant traumatic injury =< 28 days or core biopsy =< 7
days prior to randomization

- History of abdominal fistula, gastrointestinal perforation, or intraabdominal abscess
=< 6 months prior to randomization

- Known hypersensitivity to Chinese hamster ovary cell products or other recombinant
human antibodies

- History of hemoptysis >= grade 2 (defined as bright red blood of at least 2.5 mL) =< 3
months prior to randomization

- Known central nervous system (CNS) disease, except for treated brain metastasis; Note:
treatment for brain metastases may include whole brain radiotherapy (WBRT),
radiosurgery (RS); gamma knife, linear accelerator (LINAC), or equivalent or a
combination as deemed appropriate by the treating physician; patients with CNS
metastases treated by neurosurgical resection or brain biopsy performed =< 3 months
prior to randomization will be excluded; Note: craniotomy or intracranial biopsy site
must be adequately healed, free of drainage or cellulitis, and the underlying
cranioplasty must appear intact at the time of randomization; study treatment should
be initiated > 28 days following the last surgical procedure (including biopsy,
surgical resection, wound revision, or any other major surgery involving entry into a
body cavity)

- Significant vascular disease (e.g. aortic aneurysm surgical repair or recent
peripheral arterial thrombosis) =< 6 months prior to randomization

- Radiotherapy to any site for any reason =< 14 days prior to randomization

- Receiving any medications or substances that are strong or moderate inhibitors of
CYP3A4; use of the following strong or moderate inhibitors are prohibited =< 7 days
prior to randomization:

- Strong inhibitors of CYP3A4: indinavir (Crixivan), nelfinavir (Viracept),
atazanavir (Reyataz), ritonavir (Norvir), clarithromycin (Biaxin, Biaxin XL),
itraconazole (Sporanox), ketoconazole (Nizoral), nefazodone (Serzone), saquinavir
(Fortovase, Invirase), telithromycin (Ketek)

- Moderate inhibitors of CYP3A4: aprepitant (Emend), erythromycin (Erythrocin,
E.E.S, Ery-Tab, Eryc, EryPed, PCE, fluconazole (Diflucan), grapefruit juice,
verapamil (Calan, Calan SR, Covera-HS, Isoptin SR, Verelan, Verelan PM),
diltiazem (Cardizem, Cardizem CD, Cardizem LA, Cardizem SR, Cartia XT, Dilacor
XR, Diltia XT, Taztia XT, Tiazac)

- Receiving any medications or substances that are strong or moderate inducers of
CYP3A4; use of the following inducers are prohibited =< 7 days prior to randomization:
efavirenz (Sustiva), nevirapine (Viramune), carbamazepine (Carbatrol, Epitol, Equetro,
Tegretol, Tegretol-XR), modafinil (Provigil), phenobarbital (Luminal), phenytoin
(Dilantin, Phenytek), pioglitazone (Actos), rifabutin (Mycobutin), rifampin (Rifadin),
St. John?s wort
We found this trial at
19
sites
Ann Arbor, Michigan 48106
Principal Investigator: Philip J. Stella
Phone: 734-712-4931
?
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Chapel Hill, North Carolina 27599
?
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
Columbus, Ohio 43210
Principal Investigator: Gregory A. Otterson
Phone: 614-293-8574
?
mi
from
Columbus, OH
Click here to add this to my saved trials
Decatur, Illinois 62526
Principal Investigator: Bryan A. Faller
Phone: 314-996-6955
?
mi
from
Decatur, IL
Click here to add this to my saved trials
2301 Erwin Rd
Durham, North Carolina 27710
919-684-8111
Principal Investigator: Jeffrey Crawford
Phone: 919-668-6730
Duke Univ Med Ctr As a world-class academic and health care system, Duke Medicine strives...
?
mi
from
Durham, NC
Click here to add this to my saved trials
?
mi
from
East Syracuse, NY
Click here to add this to my saved trials
801 Broadway North
Fargo, North Dakota 58122
?
mi
from
Fargo, ND
Click here to add this to my saved trials
Grand Rapids, Michigan 49503
Principal Investigator: Kathleen J. Yost
Phone: 616-954-9800
?
mi
from
Grand Rapids, MI
Click here to add this to my saved trials
835 S Van Buren St
Green Bay, Wisconsin 54301
?
mi
from
Green Bay, WI
Click here to add this to my saved trials
200 Technology Drive
Hooksett, New Hampshire 03106
603-622-6484
Principal Investigator: Douglas J. Weckstein
New Hampshire Oncology - Hematology, PA - Hooksett New Hampshire Oncology-Hematology, PA (NHOH) was founded...
?
mi
from
Hooksett, NH
Click here to add this to my saved trials
3855 Health Sciences Dr,
La Jolla, California 92093
(858) 822-6100
Principal Investigator: Lyudmila A. Bazhenova
Phone: 858-822-5352
UC San Diego Moores Cancer Center Established in 1978, UC San Diego Moores Cancer Center...
?
mi
from
La Jolla, CA
Click here to add this to my saved trials
8940 Wood Sage Rd
Peoria, Illinois 61615
(309) 243-3000
Principal Investigator: Gregory J. Gerstner
Phone: 309-243-3614
Illinois CancerCare-Peoria Illinois CancerCare, P.C. is a comprehensive practice treating patients withcancer andblood diseases. Our...
?
mi
from
Peoria, IL
Click here to add this to my saved trials
353 Fairmont Blvd
Rapid City, South Dakota 57701
(605) 719-1000
Principal Investigator: Joshua C. Lukenbill
Phone: 605-755-2301
Rapid City Regional Hospital Regional Health is an integrated health care system of more than...
?
mi
from
Rapid City, SD
Click here to add this to my saved trials
Rochester, Minnesota 55905
?
mi
from
Rochester, MN
Click here to add this to my saved trials
Saint Cloud, Minnesota 56303
?
mi
from
Saint Cloud, MN
Click here to add this to my saved trials
660 S Euclid Ave
Saint Louis, Missouri 63110
(314) 362-5000
Principal Investigator: Maria Q. Baggstrom
Phone: 314-362-5737
Washington University School of Medicine Washington University Physicians is the clinical practice of the School...
?
mi
from
Saint Louis, MO
Click here to add this to my saved trials
101 East Wood Street
Spartanburg, South Carolina 29303
(864) 560-6812
Principal Investigator: James D. Bearden
Phone: 864-560-6812
Upstate Carolina CCOP Spartanburg Regional is one of the original 50 sites selected for the...
?
mi
from
Spartanburg, SC
Click here to add this to my saved trials
Syracuse, New York 13214
Principal Investigator: Stephen L. Graziano
Phone: 315-464-8237
?
mi
from
Syracuse, NY
Click here to add this to my saved trials
Urbana, Illinois 61801
Principal Investigator: James R. Egner
Phone: 217-383-3394
?
mi
from
Urbana, IL
Click here to add this to my saved trials